SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia - PubMed (original) (raw)
. 2001 Feb;296(2):312-21.
E A Irving, A M Ray, J C Lee, S Kassis, S Kumar, A M Badger, R F White, M J McVey, J J Legos, J A Erhardt, A H Nelson, E H Ohlstein, A J Hunter, K Ward, B R Smith, J L Adams, A A Parsons
Affiliations
- PMID: 11160612
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia
F C Barone et al. J Pharmacol Exp Ther. 2001 Feb.
Abstract
The stress-activated mitogen-activated protein kinase (MAPK) p38 has been linked to the production of inflammatory cytokines/mediators/inflammation and death/apoptosis following cell stress. In these studies, a second-generation p38 MAPK inhibitor, SB 239063 (IC(50) = 44 nM), was found to exhibit improved kinase selectivity and increased cellular (3-fold) and in vivo (3- to 10-fold) activity over first-generation inhibitors. Oral SB 239063 inhibited lipopolysaccharide-induced plasma tumor necrosis factor production (IC(50) = 2.6 mg/kg) and reduced adjuvant-induced arthritis (51% at 10 mg/kg) in rats. SB 239063 reduced infarct volume (48%) and neurological deficits (42%) when administered orally (15 mg/kg, b.i.d.) before moderate stroke. Intravenous SB 239063 exhibited a clearance of 34 ml/min/kg, a volume of distribution of 3 l/kg, and a plasma half-life of 75 min. An i.v. dosing regimen that provided effective plasma concentrations of 0.38, 0.75, or 1.5 microg/ml (i.e., begun 15 min poststroke and continuing over the initial 6-h p38 activation period) was used. Significant and dose-proportional brain penetration of SB 239063 was demonstrated during these infusion periods. In both moderate and severe stroke, intravenous SB 239063 produced a maximum reduction of infarct size by 41 and 27% and neurological deficits by 35 and 33%, respectively. No effects of the drug were observed on cerebral perfusion, hemodynamics, or body temperature. Direct neuroprotective effects from oxygen and glucose deprivation were also demonstrated in organotypic cultures of rat brain tissue. This robust in vitro and in vivo SB 239063-induced neuroprotection emphasizes the potential role of MAPK pathways in ischemic stroke and also suggests that p38 inhibition warrants further study, including protection in other models of nervous system injury and neurodegeneration.
Similar articles
- Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia.
Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, Legos JJ, Erhardt JA, Ohlstein EH, Hunter AJ, Harrison DC, Philpott K, Smith BR, Adams JL, Parsons AA. Barone FC, et al. Med Res Rev. 2001 Mar;21(2):129-45. doi: 10.1002/1098-1128(200103)21:2<129::aid-med1003>3.0.co;2-h. Med Res Rev. 2001. PMID: 11223862 Review. - SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia.
Legos JJ, Erhardt JA, White RF, Lenhard SC, Chandra S, Parsons AA, Tuma RF, Barone FC. Legos JJ, et al. Brain Res. 2001 Feb 16;892(1):70-7. doi: 10.1016/s0006-8993(00)03228-5. Brain Res. 2001. PMID: 11172750 - Inhibition of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death.
Barancik M, Htun P, Strohm C, Kilian S, Schaper W. Barancik M, et al. J Cardiovasc Pharmacol. 2000 Mar;35(3):474-83. doi: 10.1097/00005344-200003000-00019. J Cardiovasc Pharmacol. 2000. PMID: 10710135 - SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE. Underwood DC, et al. J Pharmacol Exp Ther. 2000 Apr;293(1):281-8. J Pharmacol Exp Ther. 2000. PMID: 10734180 - Therapeutic potential of anti-inflammatory drugs in focal stroke.
Barone FC, Parsons AA. Barone FC, et al. Expert Opin Investig Drugs. 2000 Oct;9(10):2281-306. doi: 10.1517/13543784.9.10.2281. Expert Opin Investig Drugs. 2000. PMID: 11060807 Review.
Cited by
- Increased NADPH oxidase-derived superoxide is involved in the neuronal cell death induced by hypoxia-ischemia in neonatal hippocampal slice cultures.
Lu Q, Wainwright MS, Harris VA, Aggarwal S, Hou Y, Rau T, Poulsen DJ, Black SM. Lu Q, et al. Free Radic Biol Med. 2012 Sep 1;53(5):1139-51. doi: 10.1016/j.freeradbiomed.2012.06.012. Epub 2012 Jun 19. Free Radic Biol Med. 2012. PMID: 22728269 Free PMC article. - Activation of the calcium-sensing receptor promotes apoptosis by modulating the JNK/p38 MAPK pathway in focal cerebral ischemia-reperfusion in mice.
Zhen Y, Ding C, Sun J, Wang Y, Li S, Dong L. Zhen Y, et al. Am J Transl Res. 2016 Feb 15;8(2):911-21. eCollection 2016. Am J Transl Res. 2016. PMID: 27158378 Free PMC article. - Early steps of microglial activation are directly affected by neuroprotectant FK506 in both in vitro inflammation and in rat model of stroke.
Zawadzka M, Dabrowski M, Gozdz A, Szadujkis B, Sliwa M, Lipko M, Kaminska B. Zawadzka M, et al. J Mol Med (Berl). 2012 Dec;90(12):1459-71. doi: 10.1007/s00109-012-0925-9. Epub 2012 Jul 18. J Mol Med (Berl). 2012. PMID: 22806180 Free PMC article. - Microglial activation in stroke: therapeutic targets.
Yenari MA, Kauppinen TM, Swanson RA. Yenari MA, et al. Neurotherapeutics. 2010 Oct;7(4):378-91. doi: 10.1016/j.nurt.2010.07.005. Neurotherapeutics. 2010. PMID: 20880502 Free PMC article. Review. - Inflammation in adult and neonatal stroke.
Vexler ZS, Tang XN, Yenari MA. Vexler ZS, et al. Clin Neurosci Res. 2006 Dec 1;6(5):293-313. doi: 10.1016/j.cnr.2006.09.008. Clin Neurosci Res. 2006. PMID: 20300490 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical